CoreValve, S.A. Announces Successful Completion Of World's First Pure Percutaneous Aortic Valve Replacement (PAVR) Procedure Utilizing Its Patented ReValving(TM) System

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that its patented ReValving System, consisting of a breakthrough 18-French-sized delivery catheter, was used to percutaneously implant its proprietary porcine pericardial-tissue bioprosthesis over the severely calcified aortic heart valve of an 89-year-old female patient. In contrast to long post-surgical recuperation times, this ‘pure’ PAVR patient was discharged from the ICU to the general ward on the morning after her ReValving procedure and was fully mobile and awaiting discharge from the hospital.

Back to news